Finance

Beta
Lists
4507:TYO
Shionogi & Co Ltd
JP¥2 876,00
+1,18%
(+33,50) 1D
17 Jul., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4507...
Open
JP¥2 858
High
JP¥2 929
Low
JP¥2 848
Mkt. cap
2,56 bn
Avg. vol.
2,55 m
Volume
3,51 m
Dividend
2,47%
Quarterly dividend
JPÂ¥18
Ex-dividend date
29 Sep. 2025
P/E ratio
11,93
52-wk high
JP¥3 758
52-wk low
JP¥2 392
EPS
JPÂ¥241
Shares outstanding
314,50 m
No. of employees
6 k
Open
JP¥2 858
High
JP¥2 929
Low
JP¥2 848
Mkt. cap
2,56 bn
Avg. vol.
2,55 m
Volume
3,51 m
Dividend
2,47%
Quarterly dividend
JPÂ¥18
Ex-dividend date
29 Sep. 2025
P/E ratio
11,93
52-wk high
JP¥3 758
52-wk low
JP¥2 392
EPS
JPÂ¥241
Shares outstanding
314,50 m
No. of employees
6 k
News stories
From sources across the web
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6,22 k
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com
Next call oor 14 dae
Ma. 3 Aug., 10:00
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
- / 158,67 mjd
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
99,78 mjd
113,18 mjd
147,72 mjd
138,99 mjd
Cost of goods sold
12,32 mjd
16,94 mjd
25,09 mjd
28,10 mjd
Cost of revenue
12,32 mjd
16,94 mjd
25,09 mjd
28,10 mjd
Research and development expenses
24,89 mjd
27,55 mjd
29,87 mjd
40,54 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25,82 mjd
27,56 mjd
35,27 mjd
32,92 mjd
Operating expense
52,37 mjd
56,57 mjd
48,45 mjd
100,06 mjd
Total operating expenses
64,68 mjd
73,51 mjd
73,54 mjd
128,17 mjd
Operating income
35,10 mjd
39,67 mjd
74,18 mjd
10,83 mjd
Other non operating income
-1,00 m
-
-1,00 m
7,31 mjd
EBT including unusual items
46,33 mjd
52,06 mjd
92,89 mjd
47,64 mjd
EBT excluding unusual items
46,33 mjd
52,06 mjd
93,10 mjd
47,80 mjd
Income tax expense
6,98 mjd
7,87 mjd
18,21 mjd
-56,00 m
Effective tax rate
15,07%
15,12%
19,60%
-0,12%
Other operating expenses
1,17 mjd
979,00 m
-17,25 mjd
15,44 mjd
Net income
39,36 mjd
44,19 mjd
74,68 mjd
46,93 mjd
Net profit margin
39,44%
39,04%
50,56%
33,77%
Earnings per share
-
-
-
-
Interest and investment income
13,56 mjd
14,21 mjd
20,53 mjd
23,73 mjd
Interest expense
-2,33 mjd
-1,82 mjd
-1,61 mjd
-
Net interest expenses
11,23 mjd
12,38 mjd
18,92 mjd
23,73 mjd
Depreciation and amortization charges
-
-485,00 m
-
-1,53 mjd
EBITDA
40,11 mjd
44,83 mjd
80,21 mjd
21,59 mjd
Gain or loss from assets sale
-
-
-
35,04 mjd
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer